Microgynon Riociguat Drug Interaction Study to Investigate the Effect of Riociguat 2.5 mg 3 Times Daily Multiple-dose Treatment on the Plasma Concentrations of / Exposure to Levonorgestrel and Ethinyl Estradiol in Healthy Postmenopausal Women in a 2-fold Crossover Design

Trial Profile

Microgynon Riociguat Drug Interaction Study to Investigate the Effect of Riociguat 2.5 mg 3 Times Daily Multiple-dose Treatment on the Plasma Concentrations of / Exposure to Levonorgestrel and Ethinyl Estradiol in Healthy Postmenopausal Women in a 2-fold Crossover Design

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2015

At a glance

  • Drugs Riociguat (Primary) ; Ethinylestradiol/levonorgestrel
  • Indications Pulmonary arterial hypertension; Pulmonary hypertension; Raynaud's disease; Systemic scleroderma
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 25 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 09 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 04 Feb 2015 Planned End Date changed from 1 Jan 2015 to 1 Mar 2015 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top